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Drug developmenta b s t r a c t
2-Arachidonoylglycerol (2-AG) is an endocannabinoid that activates the cannabinoid receptors type 1
and 2. It also serves as an important lipid precursor for the eicosanoid signaling pathway.
Consequently, 2-AG is involved in many physiological functions, including anxiety, food intake, inflam-
mation, memory, pain sensation and neurotransmission. Diacylglycerol lipases (DAGLs) are the main
biosynthetic enzymes for 2-AG and their role in several pathophysiological conditions is currently under
investigation. In this Digest we review all DAGL inhibitors reported to date and their effects in preclinical
models of neurodegeneration and metabolic disorders.
 2016 Elsevier Ltd. All rights reserved.2-Arachidonoylglycerol (2-AG) is an important endogenous sig-
naling lipid. 2-AG activates the cannabinoid receptors type 1 and 2
(CB1R and CB2R) and is, therefore, termed an endocannabinoid.1–3
Multiple lipid species can activate the CBRs, but 2-AG, together
with anandamide, is the most well studied endocannabinoid. 2-
AG contributes to CB1R mediated synaptic plasticity and acts as a
retrograde messenger inhibiting GABAergic and glutamatergic
neurotransmission.4,5 The CBRs are involved in many physiological
functions, including food intake,6–8 inflammation,9,10 memory for-
mation,11–13 mood,14,15 locomotor acivity,16,17 pain sensation,18
addiction and reward.19 The exact contribution of 2-AG to these
physiological processes remains poorly understood. The levels of
2-AG are tightly regulated in the central nervous system, because
it is produced on demand and rapidly degraded by specialized
enzymes.20–22 Phospholipase C-b (PLCb) catalyses the formation
of diacylglycerols from cell membrane phospholipid phos-
phatidylinositol-4,5-bisphosphate (PIP2). Diacylglycerols are sub-
sequently converted by sn-1 specific diacylglycerol lipases a and
b (DAGLs) to monoacylglycerols, including 2-AG.20 DAGLs belongto the large family of serine hydrolases, having a typical a/b hydro-
lase fold and Ser-His-Asp catalytic triad. The two DAGL isoforms
(a and b) share extensive homology and differ mostly in a large
C-terminal tail, which is present in DAGLa, but not in DAGLb.20
Genetic disruption of DAGLa in mice resulted in a strong reduction
of 2-AG levels in the brain (80–90%), whereas in DAGLb/ mice the
2-AG level was approximately 50% reduced in the brain.4,5 2-AG is
mainly metabolized by monoacylglycerol lipase (MAGL) and to a
lesser extent by a/b-hydrolase domain proteins 6 and 12 (ABHD6
and ABHD12). This leads to the production of arachidonic acid
(AA).22 Both 2-AG and AA may serve as substrates for oxidative
enzymes (cyclooxygenases) yielding pro-inflammatory prostaglan-
dins and their ester derivatives, respectively (Fig. 1).23 Inhibitors of
MAGL have contributed to the understanding of the physiological
role of 2-AG (see for recent reviews24–26) and are currently tested
in preclinical models and clinical trials for neurodegenerative dis-
eases. Here, we will review the current state of the art of the dia-
cylglycerol lipases inhibitors and discuss their potential in
metabolic disorders and neurodegeneration.
Assays to measure DAGL activity: Several DAGL activity assays
are currently available. The first class of assays employs surrogate
substrates, i.e., para-nitrophenylbutyrate, 6,8-difluoro-4-methy-
lumbelliferyl (DiMFU) octanoate and EnzChek, and is generally
used for inhibitor identification.28–31 The main advantage is that
product formation can be monitored real-time, generally by
























Figure 1. Overview of the biosynthetic pathway of 2-AG. Phospholipase C-b (PLCb) converts membrane associated phosphatidylinositol-4,5-bisphosphate (PIP2) to
diacylglycerol (DAG), which in turn acts as substrate for sn-1 specific diacylglycerol lipases a and b (DAGLs).20 DAGLs produce endocannabinoid 2-arachidonoylglycerol (2-
AG), a ligand for the cannabinoid receptors type 1 and 2 (CB1 and CB2). 2-AG is degraded by several enzymes including monoacylglycerol lipase (MAGL), a/b hydrolase
domain 6 and 12 (ABHD6 and ABHD12) to arachidonic acid (AA), which serves as a precursor for the formation of several distinct eicosanoids, such as proinflammatory
prostaglandin PGE2 and thromboxane TBX2. Other oxidative pathways involved in AA degradation include cytochrome P450 (CYP) and 5-lipoxygenase (5-LOX) to produce
epoxyeicosanoids and leukotrienes, respectively, while direct oxidation of 2-AG by COX2 may result in the formation of prostaglandin-esters.23,27
3832 F. J. Janssen, M. van der Stelt / Bioorg. Med. Chem. Lett. 26 (2016) 3831–3837and easy detection of surrogate substrates/products make these
assays valuable tools for high-throughput screening applica-
tions.28,30,32 However, surrogate substrates generally have attenu-
ated binding affinities for the enzyme compared to DAGLs’
natural substrate sn-1-stearoyl-2-arachidonoyl-glycerol. This may
affect inhibitor potencies (IC50) obtained with these assays. Conse-
quently, the use of the natural substrate is preferred for further
inhibitor profiling.
The second class of assays makes use of a natural substrate of
DAGLs. Radiometric assays have been used to measure DAGLa
activity in vitro, utilizing radiolabeled diacylglycerol, such as sn-
1-stearoyl-2-[14C]arachidonoylglycerol, as a substrate.20 This
method is highly sensitive, but requires lipid extraction, fractiona-
tion on thin layer chromatography and quantification of radiola-
beled 2-[14C]arachidonoylglycerol via scintillation counting,
thereby making this assay labor-intensive. Of note, the radioactive
substrate it is not commercially available. This restricts the wide-
spread use of the radiometric assay. Alternatively, liquid chromato-
graphic (LC) methods coupled to mass spectrometry (MS), have
been employed to measure direct 2-AG formation.33 Although,
LC/MS methods avoid the use of radiolabeled substrates and are
highly accurate, it does require lipid extraction and separation of
phases. Consequently, only limited number of samples can be mea-
sured. Both radiometric and LC/MS-based assays prohibit monitor-
ing of reaction progress in real-time due to their discontinuous
setup. Therefore, a third method was recently developed, in which
the conversion of the natural substrate 1-stearoyl-2-arachidonoyl-
sn-glycerol (SAG) was coupled to the formation of a fluorescent dye
employing a five enzyme cascade.34 Extraction or fractionation
steps were not necessary allowing SAG hydrolysis to be studied
in real time in 96-well plate format using recombinant DAGLa or
DAGLb as well as mouse brain membrane fractions.34,35
Finally, the third class of assays employs activity-based protein
profiling (ABPP). ABPP is a chemical biological technique that
allows the rapid and efficient visualization of endogenous serine
hydrolase activity in complex, native samples without the need
of having substrate assays.36,37 Typically, ABPP is used in a compet-
itive setting, where a pool of enzymes is treated with an inhibitor,
followed by a broad spectrum or tailored activity-based probe
(ABP) that labels all residual serine hydrolase activity. The ABP
reporter tag allows for identification and quantification of inhibitor
off-targets that are shared by the probe, using either in-gelfluorescence scanning or mass spectrometry. As such, ABPP mea-
sures activity and selectivity of irreversible and reversible inhibi-
tors in cells and tissue lysates,38 making it a highly valuable and
complementary method next to classical substrate assays. Three
different tailored ABPs have been developed for the detection of
DAGL activity in proteomes: HT-01,33 MB06439 and DH379.35
DAGL inhibitor classes: To date, six different chemotypes have
been reported as DAGL inhibitors, which can be classified into (a)
reversible inhibitors: a-ketoheterocycles and glycine sulfon-
amides, and (b) irreversible inhibitors: bis-oximino-carbamates,
b-lactones, fluorophosphonates and 1,2,3-triazole ureas.
a-Ketoheterocycles: Using an ABPP-screen with the tailored
activity-based probe MB064 and a pharmacophore model, Bagge-
laar et al. identified the a-ketoheterocycle LEI104 (Fig. 2) as the
first reversible inhibitor for DAGLa. LEI104 was, however, weakly
active in a cellular assay and not selective over FAAH, the enzyme
responsible for the metabolism of the other endocannabinoid
anandamide (Table 1).39 The structure activity relationships
(SAR) of the a-ketoheterocycles were investigated by screening a
focussed library of 1040 compounds. The a-keto group functioned
as an electrophilic warhead and its reactivity could be tuned by
selection of appropriate substituents on the scaffold. The 4N-oxa-
zolopyridine heterocycle proved to be the most optimal scaffold
and compounds with a C6–C9 methylene phenyl acyl substituent
were the most potent inhibitors.32 Using this extensive SAR, a
DAGLa homology model was validated and applied to the design
of LEI105, a p-tolyl derivative of LEI104 (Fig. 2).40 Competitive
and comparative chemoproteomics revealed that LEI105 was a
highly potent and selective, covalent reversible inhibitor of DAGLa
and DAGLb, which did not target other proteins in the endo-
cannabinoid system, including CB1R and CB2R, ABHD6, ABHD12,
MAGL and FAAH (Table 1). LEI105 dose-dependently reduced 2-
AG levels in neuronal cells without affecting anandamide levels.
Finally, LEI105 attenuated synaptic plasticity by blocking depolar-
ization-induced suppression of inhibition (DSI) in CA1 pyramidal
neurons in mouse hippocampal slices. LEI105 has not been tested
in in vivo models yet.
Glycine sulfonamides: The glycine sulfonamides were reported
by Appiah et al. as the first non-covalent reversible inhibitors of
DAGL.28 Their high throughput screening campaign identified com-
pound 1 as a DAGLa inhibitor, which was selective over MAGL and
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Figure 2. Current DAGL chemotypes and their corresponding inhibitors.20,28,33,35,41,43,48,55,56,58
F. J. Janssen, M. van der Stelt / Bioorg. Med. Chem. Lett. 26 (2016) 3831–3837 3833sulfonamides lack an obvious warhead that can covalently interact
with the catalytically active serine in the enzyme. SAR studies
revealed that the sulfonamide was required for proper positioning
of the side groups, probably due to its characteristic perpendicular
angle, and the carboxylate was essential for activity.41 Based on the
initial hit compound 1, and patent literature,42 LEI106 (Fig. 2) was
identified as a DAGL inhibitor with nanomolar potency. ABPP
revealed LEI106 to be selective over MAGL, but ABHD6 and two
additional unknown off-targets were inhibited (Table 1). Docking
of LEI106 in a DAGLa homology model suggested that the carboxy-
late interacted with an intricate hydrogen bonding network of the
catalytic triad. Recently, Chupak et al. published a full account of
their extensive optimization of the glycine sulfonamides, which
resulted in the identification of compounds 3 and 24 (Fig. 2,
Table 1).43 They found that glycine sulfonamide 3 is a cellular
active and orally bio-available DAGLa/b inhibitor. Due to potential
toxicity issues associated with biphenyl-amines, compound 3 was
further optimized to compound 24. The latter compound was a
peripherally restricted, highly potent and dual DAGLa/b inhibitor
with some minor affinity for the human ether-a-go-go channel
(IC50 = 40 lM) and a good pharmacokinetic profile.43 No additional
functional or in vivo efficacy data have been reported with this ser-
ies to date.
Bis-oximino-carbamates: RHC80267 (Fig. 2) was one of the first
DAGL inhibitors reported in the literature, but it is only weakly
active on DAGLa and not selective. RHC80267 inhibited at least 7
others targets, including fatty acid amide hydrolase (FAAH) and
lipoprotein lipase (LPL, see Table 1).39,44 This activity and selectiv-
ity profile makes it less suitable to study the biological role of
DAGLs.
b-Lactones: Tetrahydrolipstatin (THL, Orlistat, Fig. 2) is a
peripherally restricted, FDA approved anti-obesity drug (Xenigal,
Alli) that inhibits gastric and pancreatic lipases, which are
essential for fat processing in the gastrointestinal track.45–47 Sincethe discovery of THL as a potent DAGL inhibitor,20 b-lactones
have been extensively investigated as DAGL inhibitors with a
focus on changing the amino acid substituent on the chiral d-
hydroxyl moiety.48,49 THL inhibited DAGLa and DAGLb with
nanomolar potency in natural substrate assays to a similar extent
(Table 1). OMDM-188, a N-formyl-L-isoleucine derivative of THL
(Fig. 2), demonstrated improved selectivity over FAAH and MAGL,
but micromolar antagonistic activity on the CB1R (Ki = 6 lM,
Table 1). This may complicate the interpretation of results
obtained with this compound, if the in vitro studies are carried
out at high inhibitor concentration (>10 lM).48 OMDM-188 has
been used to investigate whether 2-AG is released ‘on demand’
or from preformed pools during neuronal activity. While some
studies with THL and OMDM-188 show that acute DAGL inhibi-
tion attenuates DSI in hippocampal CA1 pyramidal cells,50,51
other studies with the same inhibitors found no such effect.52
The discrepancy between the various electrophysiological studies
could be potentially attributed to differences in tissue penetra-
tion of the compounds, due to their relatively high lipophilicity,50
but off-targets effects cannot be ruled out either. Recent studies
using novel DAGL inhibitors, such as LEI10540 and 1,2,3-triazole
ureas,35 have confirmed that CB1R-mediated synaptic plasticity
is dependent on acute DAGL activity, which supports the hypoth-
esis of ‘on demand’ production of 2-AG.
Recently, OMDM-188 has been used to study the biological role
of DAGLa in gastrointestinal motility. Bashashati et al. showed that
DAGLa is expressed throughout the enteric nervous system and its
inhibition by OMDM-188 reversed slowed gastrointestinal motil-
ity, intestinal contractility and constipation through a CB1R depen-
dent mechanism.53 Conversely, inhibition of MAGL prolonged the
whole gut transit time.54 These studies suggest that DAGLa is a
potential target for the treatment of constipation. 2-AG levels in
the ileum or colon of the genetically constipated mice were, how-
ever, not significantly affected and the effect of OMDM-188 on
Table 1
Overview of known DAGL inhibitors per assaytype and chemotype, values are pIC50
Chemotype Compound Surrogate substrate assay Natural substrate assay ABPP assay Identified off-targets




















OMDM-188 8.2 (b)iii 7.8 (a)vi — CB1 (minor)48




O-3841 — 6.8 (a)vi — None reported55
O-5596 — 7.0 (a)vi — None reported56
O-7460 — 6.2 (a)vi — KIAA136358




























a-Keto heterocycles LEI104 7.4 (a)x 6.3 (a)vi 6.3 (a)xi FAAH40,64
LEI105 8.5 (a)x 6.6 (a)vi
7.9 (a)xi
7.6 (a)xi None reported40
(FAAH selective)
Glycine sulfonamides 1 6.3 (a)xii — — None reported28
3 8.6 (a)xii
7.4 (b)xii
— — None reported43
24 9.2 (a)xii
7.4 (b)xii
— — hERG (minor)43




Conditions: (i) Pedicord et al., colorimetric surrogate substrate assay: 4.3 lg/mL hDAGLa overexpressing HEK293F membrane fractions, 250 lM PNP butyrate.30 (ii) Pedicord
et al., fluorogenic surrogate substrate assay: 4.0 lg/mL hDAGLa overexpressing HEK293F membrane fractions, 10 lM DiMFU-octanoate.30 (iii) Singh et al., fluorogenic
surrogate substrate assay: 12.5 lg/mL purified GST-DAGLb CD, 5 min preincubation, then 2 lM EnzChek.29 (iv) Van der Wel et al., Enzyme coupled natural substrate assay:
50 lg/mL hDAGLa overexpressing HEK293T membrane fractions, 20 min preincubation, 100 lM SAG.34,35 (v) Bisogno et al. 2003, Radiometric natural substrate assay: DAGL
overexpressing COS-7 membrane fractions, 15 min preincubation at 37 C, 14C labeled diacylglycerol 50 lM.20 (vi) Bisogno et al. 2006, Radiometric natural substrate assay:
DAGL overexpressing COS-7 membrane fractions, 20 min preincubation at 37 C, 14C labeled diacylglycerol 25 lM.41,48,55,58 (vii) Hsu et al., ABPP: 2 mg/mL hDAGLa or
mDAGLb hDAGLa overexpressing HEK293T membrane fractions, 30 min preincubation at 37 C, then ABP HT01, 1 lM, 30 min incubation.33 (viii) Hsu et al., LC–MS natural
substrate assay: 300 lg/mL mDAGLb overexpressing HEK293T membrane fractions, 30 min preincubation at 37 C, 500 lM SAG.33 (ix) Ogasawara et al., Enzyme coupled
natural substrate assay: 50 lg/mL mDAGLb overexpressing HEK293T membrane fractions, 5 mM CaCl2, 20 min preincubation, 75 lM SAG.35 (x) Baggelaar et al., Colorimetric
surrogate substrate assay: 50 lg/mL DAGLa overexpressing HEK293T membrane fractions, 20 min preincubation, 300 lM PNP butyrate.39–41 (xi) Baggelaar et al, Activity
based protein profiling: Mouse brain proteome 2 mg/mL, 30 min preincubation, then ABP MB064, 250 nM, 15 min incubation.39–41 (xii) Appiah et al., Fluorogenic surrogate
substrate assay: 12.0 lg/mL DAGLa overexpressing membranes, 10 lM DiMFU-octanoate.28,43
3834 F. J. Janssen, M. van der Stelt / Bioorg. Med. Chem. Lett. 26 (2016) 3831–3837pancreatic and gastrointestinal lipase is currently unknown. Fur-
ther studies may address these questions.
Fluorophosphonates: O-3640, O-3841 and O-5596 covalently
inhibit DAGL and are mimetics of the endogenous lipid 2-oleoyl-
glycerol carrying a fluorophosphonate group as a warhead
(Fig. 2).55,56 These compounds have nanomolar potency in a natu-
ral substrate assay and, in particular O-3841 and O-5596 show few
off-target activities (Table 1).55,56 O-3640 and O-3841 have, how-
ever, little to no effect in a cellular assay in which ionomycin is
used to stimulate the formation of 2-AG in N18TG2 cells. The lack
of cellular activity is perhaps due to chemical instability of the
inhibitors or low cell membrane permeability.55,56 Remarkably,
O-3841 was neuroprotective in a malonate model of Huntington’s
disease.57 O-3841 prevented the formation of prostaglandin E2
glyceryl ester that exerted neurotoxicity, whereas MAGL-inhibitorsexacerbated neuronal damage. Optimization of the substituent at
the sn-3 position of O-3841 led to the identification of O-7460
(Fig. 2), which was moderately active on human DAGLa
(IC50 = 690 nM) and reduced 2-AG levels in situ. Neutral choles-
terol ester hydrolase 1 (KIAA1363) was detected with ABPP as an
important off-target. O-5596 and O-7460 decreased the amount
of palatable food ingested by mice in a dose-dependent manner
and slightly reduced body weight.56,58 These observations are in
line with the results obtained with DAGLa KO mice (see below).59
1,2,3-Triazole ureas: DAGL inhibitors based on the 1,2,3-triazole
urea scaffold have been instrumental to determine the physiolog-
ical role of DAGLs in macrophages and brain. Hsu et al. developed
the first DAGLb inhibitors that were active in an in vivo model of
inflammation.33 KT109 and KT172 (Fig. 2), but not KT195, a control
compound, reduced the levels of 2-AG, AA and eicosanoids
F. J. Janssen, M. van der Stelt / Bioorg. Med. Chem. Lett. 26 (2016) 3831–3837 3835(thromboxane A2, leukotriene B4, prostaglandin D2 and E2) in
peritoneal macrophages of lipopolysaccharide (LPS)-treated
mice.33 Moreover, KT109 and KT172 significantly decreased proin-
flammatory cytokine tumor necrosis factor a (TNFa) in LPS-treated
mice. This demonstrated that DAGLb plays a pivotal role in the reg-
ulation of macrophage inflammatory response in vivo. Of note,
KT109 does inhibit DAGLa (Table 1) and depending on its concen-
tration and time of incubation, DAGLa may be fully inhibited.
KT109 and KT172 do not act in the central nervous system, pre-
sumably, because they are not able to cross the blood–brain bar-
rier. Wilkerson et al. investigated the effect of DAGLb inhibition
on inflammatory and neuropathic pain.60 Local inhibition of DAGLb
by KT109 at the site of inflammation reduced LPS-induced allody-
nia in mice, whereas general i.c.v. or i.t administration was ineffec-
tive. This suggests that peripheral inhibition of DAGLb may
represent a novel avenue to treat pathological pain.60
To investigate the biological role of DAGLs in the brain, Oga-
sawara et al. developed the triazole ureas DH376 and DO34
(Fig. 2). DH376 and DO34 were highly potent and selective DAGL
inhibitors.35 ABPP experiments demonstrated a limited off-target
profile for DH376 and DO34 in the brain and designated DO53 as
a paired control compound. Both DAGL inhibitors, but not DO53,
fully blocked GABAergic (DSI) and glutamatergic (DSE) neurotrans-
mission in hippocampal and cerebellar slices, respectively. Acute
blockade of DAGL in mice produced a striking reorganization of
bioactive lipid networks, including elevations of DAGs and reduc-
tions in endocannabinoids and eicosanoids. For example, dose-
and time-dependent reductions in 2-AG, AA and PGE2 levels were
observed in the brain of mice treated i.p. with DO34 or DH376,
but not with DO53. Importantly, the in vivo half-life of DAGLa
was short (2–4 h) and accompanied by ongoing DAGLa protein
production in the brain that generated a strong, tonic flux of 2-
AG. It was suggested that modulation of DAGLa half-life may thus
provide neurons with a mechanism to influence the magnitude and
duration of 2-AG signaling and associated physiological processes,
such as learning and memory.35 Of note, anandamide levels were
also affected by DAGL inhibition by DH376 and DO34 and not by
control compound DO53. The molecular mechanism underlying
this in vivo cross-talk between the two endocannabinoids is not
clear at the moment, but was also observed in DAGL KO ani-
mals.4,5,61 DAGL inhibition by DH376 and DO34 reduced the forma-
tion of 2-AG, AA and proinflammatory prostaglandins as well as
pro-inflammatory cytokine IL1b upon LPS-treatment in mice.35
DAGL inhibition also attenuated LPS-induced anapyrexia (reduc-
tion of core body temperature), which is contrast to enhanced ana-
pyrexia mediated by acute blockade of MAGL.62 This suggests that
2-AG has an important role in the regulation of body temperature
during neuroinflammation. Viader et al. demonstrated by com-
bined genetic and pharmacological evaluation that disruption of
either DAGLa or DAGLb contributes to lower the neuroinflamma-
tory response in vivo.75 They found that DAGLb is key in regulating
2-AG levels in microglia and that LPS treated DAGLb/ mice show
attenuated microglial activation without changes in overall 2-AG
and prostaglandin levels in brain.
Buczynski et al. showed that inhibition of DAGL by KT172
(Fig. 2), but not control compound KT185, restores GABAergic sig-
naling at dopaminergic neurons in the ventral tegmental area
(VTA), which is lost during chronic nicotine exposure.63 Accord-
ingly, rats treated with KT172 significantly less self-administered
nicotine without affecting other operant response or locomotion.
This may indicate that the 2-AG signaling, mediated by DAGLa, is
involved in the regulation of reward and addiction.
Therapeutic potential of DAGL inhibitors in anti-obesity and neuro-
protection: The endocannabinoid system is a clinically proven sig-
naling pathway controlling the energy balance in humans. In
fact, the first generation CB1R antagonist/inverse agonistRimonabant was considered one of the most promising therapeutic
drugs to treat human obesity, until the appearance of central psy-
chiatric side effects resulted in its removal from the market in
2008.65–67 Rimonabant reduced food intake, body weight and waist
circumference in obese patients and improves cardiovascular risk
factors.65,66,68 Currently, several lines of evidence suggest that 2-
AG, and not anandamide (nor constitutively active CB1Rs), regu-
lates CB1R-dependent food intake. 2-AG levels are increased in
the hypothalamus of fasting mice7 and pharmacological interven-
tion using O-5596 and O-7460 leads to reduced food intake in
mice.58 Third, DAGLa/ mice showed hypophagia and leanness
similar to that of CB1/ mice, while knockout mice of DAGLb
and N-acyl phosphatidylethanolamine phospholipase D (NAPE-
PLD, the main enzyme responsible for anandamide synthesis) did
not share this phenotype.59,61 Interestingly, DAGLa knockout mice
had also low fasting insulin, triglyceride, and total cholesterol
levels, and after glucose challenge had normal glucose but very
low insulin levels.59 Taken together, these data suggest that selec-
tive interference with DAGLa signaling may represent a novel ther-
apeutic avenue to treat obesity and the metabolic syndrome.
Inflammatory processes are associated with obesity and with
many neurodegenerative diseases, including stroke, Parkinson’s
and Alzheimer’s disease.69 Prostaglandins produced by cyclooxyge-
nases from arachidonic acid (AA) are important pro-inflammatory
stimuli. Cyclooxygenase inhibitors show neuroprotection in animal
models of Parkinson’s and Alzheimer’s disease, but their gastroin-
testinal and cardiovascular actions have limited their use in
humans.70 Nomura et al. discovered that MAGL regulates AA levels
in specific tissues, which is required for prostaglandin synthesis by
cyclooxygenases type 1 and 2 (COX1 and COX2).71 For instance,
MAGL is the predominant enzyme producing AA in the brain, liver
and lung, whereas phospholipase A2 (PLA2) regulates AA levels in
the gut and spleen. Inhibition of MAGL activity in LPS-treated mice
resulted in an attenuated neuroinflammatory response as wit-
nessed by a marked decrease in pro-inflammatory prostaglandins
and cytokine formation in the brain. MAGL inhibitors improved
neurological outcome in animal models of Multiple Sclerosis,72
Parkinson’s71,73 and Alzheimer disease,24 thereby providing
proof-of-principle for therapeutic intervention using this biochem-
ical pathway in various models of neuroinflammation and neu-
rodegeneration. Of note, CB1R activation by elevated 2-AG levels
did not seem to be involved in the protective response. Concomi-
tant chronic activation of the CB1R by elevated 2-AG levels has pre-
viously been shown to lead to adaptations of the endocannabinoid
system (e.g., down regulation of CB1R and physical dependence).74
It is currently unknown how elevated 2-AG levels will impact
CB1R-mediated signaling under chronic neurodegenerative condi-
tions. Therefore, DAGL inhibition may provide an alternative
approach to reduce AA formation in the brain without accumula-
tion of 2-AG and (chronic) CB1R activation. The first studies with
1,2,3 triazole ureas DH376 and DO34 have demonstrated that
DAGLs regulate the formation of proinflammatory prostaglandins
and cytokines under neuroinflammatory conditions.35 The efficacy
of DAGL inhibitors in mouse models of Multiple Sclerosis, Parkin-
son’s and Alzheimer’s diseases have, however, not been reported
yet. Of note, in a malonate model of Huntington’s disease DAGL
inhibitors conferred neuroprotection, whereas MAGL inhibitors
exacerbated neuronal damage.27,57 Oxidative metabolism of 2-AG
was suggested to result in the formation of toxic metabolites.57
In conclusion, it will be important to determine the efficacy and
therapeutic window of both MAGL and DAGL inhibitors in parallel
with respect to CB1R mediated adverse effects and activation of
alternative metabolic pathways.
Potential adverse side effects of DAGL inhibitors: Suppression of
CB1R signaling with antagonists such as Rimonabant, is linked to
neuropsychiatric side effects, including anxiety and depression.76
3836 F. J. Janssen, M. van der Stelt / Bioorg. Med. Chem. Lett. 26 (2016) 3831–3837The exact contribution of DAGLs in the regulation of emotion has
been studied with DAGLa knockout mice. These studies indicate
that 2-AG signaling is also important for the regulation of neu-
ropsychiatric behavior.61,59,77 For example, Jenniches et al.
reported that DAGLa/ mice display significantly reduced mater-
nal care, increased anxiety in light/dark box and open field tests,
reduced fear extinction and increased behavioral despair.61 Powell
et al. noted similarities in behavioral phenotypes of CB1/ mice
and DAGLa/ in the hot plate, marble burying, open-field rearing,
forced swim and open-field distance traveled tests, which were dif-
ferent from their wild type counter parts. Importantly, there were
some phenotypic differences between the CB1 and DAGLa knock-
out mice. In particular, DAGLa knockout mice demonstrated anxi-
olytic responses in platform tests and in the open field test, which
were not observed with CB1/ mice.59 Shoneshy et al. noted
increased anxiety in both male and female DAGLa/ mice, while
only female mice displayed increased anhedonia.77 Several studies
indicate that perturbation of DAGLa activity, surprisingly, also
decreased anandamide levels.4,5,35,61 The consequences of this
in vivo cross-talk between the two biosynthetic pathways in rela-
tion to potential neuropsychiatric behavior is not known to date.
Interestingly, partial restoration of 2-AG levels in DAGL/ mice
by treatment of a MAGL inhibitor normalized the anxiety-related
behavior.77 DAGL inhibitors that produce a graded, dose-depen-
dent blockade of 2-AG production in the CNS, such as DH376 and
DO34, may, therefore, provide an excellent opportunity to test
whether a therapeutic window can be established. In addition,
selective DAGLb inhibitors could be of therapeutic importance
since disruption of DAGLb activity has been shown to attenuate
neuroinflammatory response in vivo without affecting synaptic
transmission.75Box 1. Important questions regarding DAGL inhibitors in meta-
bolic and neurological disorders
General
–Can we develop truly subtype-selective (peripherally
restricted) DAGL inhibitors?
–Does chronic DAGL inhibition alter CB receptor
sensitivity?
–Does pharmacological DAGL inhibition induce anxiety,
stress and fear responses?
–Can a therapeutic window be established using (rever-
sible) DAGL inhibitors?
–Can we uncouple anandamide and 2-AG biosynthesis
using DAGL inhibitors?
Metabolic disorders
–Can centrally active selective DAGLa inhibitors reduce
food seeking behavior and induce weight loss, without
inducing neuropsychiatric side effects?
–Can peripherally restricted DAGL inhibitors induce
weight loss, improve cardiovascular risk factors and
decrease insulin resistance?
Neurological disorders
–Can selective DAGL inhibitors reduce negative reward
associated behavior and contribute to the treatment of
drug abuse (e.g alcohol or opioids)?
–What is the specific role 2-AG signaling during neu-
roinflammation (i.e. DAGL versus MAGL inhibition)?
–Are DAGL inhibitors effective in models of neurodegen-
erative disease (Alzheimer’s and Parkinson’s disease,
MS, etc.)?To conclude, the development of DAGL knockout mice in com-
bination with in vivo active DAGL inhibitors have greatly con-
tributed to the understanding of the physiological role of DAGLs.
Recent findings suggest that DAGL inhibition may be beneficial in
the treatment of metabolic disorders, such as obesity, diabetes
and metabolic syndrome, as well as neuroinflammation, addiction
and pathological pain. Exciting times lay ahead as several drug dis-
covery efforts to further optimize DAGLs inhibitors are ongoing.
Several important questions still need to be addressed (See
Box 1). For example, can we develop orally, bioavailable, subtype
selective and centrally active DAGL inhibitors? In addition, periph-
eral restricted subtype selective inhibitors would also be of inter-
est. This would complete the set of chemical tools required to
elucidate the specific roles of DAGLa and b in the various tissues.
From a therapeutic point of view, the establishment of a therapeu-
tic window over the untoward neurological outcomes could per-
haps best be achieved with reversible, selective DAGL inhibitors.Acknowledgement
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